N/A N=131 Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=34 Neoadjuvant and Adjuvant Checkpoint Blockade
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Phase 2 N=100 Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Phase 2 N=56 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=6 PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Cancer
Primary: Microvascular Damage/Endothelial Dysfunction — 0 Participants
Phase 1 N=20 Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Squamous Cell Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity
Phase 2 N=16 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
Phase 2 N=27 Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma
Primary: Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events. — 13; 14; 0 Participants
Phase 2 N=20 Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate Using RECIST v1.1 to Nivolumab and Ipilimumab When Administered in Combination to Patients With Pre-treated Advanced NSCLC Who Have Experienced…
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
Phase 4 N=1,041 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Lung Cancer
Primary: Number of Participants With High Grade (Grade 3-4 and Grade 5) Drug-Related Select Adverse Events (AEs) — 19; 15; 4; 0 Participants
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Phase 1 N=16 Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Esophageal Cancer · Cancer of the Esophagus
Primary: Safety as Measured by Number of Participants With Grade 3 or Higher Treatment Related Adverse Events — 1; 1; 1; 1 Participants
Phase 2 N=7 TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Metastatic Ovarian Cancer
Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants
Phase 2 N=94 Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
Cervical Cancer
Primary: Change in Immunologic Markers Following Combination of Study Drug With Chemoradiation — 31.31; 140.33 ratio of cells per mm^2", "CD8+: FoxP3+
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Phase 2 N=47 Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 35.7 percentage of participants
Phase 2 N=64 Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Phase 2 N=1,131 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
Phase 3 N=5 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Phase 2 N=21 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
Non-small Cell Lung Cancer · Non Small Cell Lung Cancer · NSCLC
Primary: Overall Response Rate (ORR) — 1 Participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=164 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
Locally Advanced Bone Sarcoma · Locally Advanced Dedifferentiated Liposarcoma · Locally Advanced Gastrointestinal Stromal Tumor
Primary: Number of Participants Who Achieved a Confirmed Response — 2; 6; 1; 2 Participants
Phase 2 N=14 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants
Phase 1 N=3 Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Metastatic Solid Tumors · Treatment-Refractory Cancers
Primary: Maximum Tolerated Dose (MTD) at Which Dose-Limiting Toxicities (DLT) Occurred With rhIL-15 Administered in Combination With Fixed Doses of Nivolumab and Ipilimumab — 1.0…